JP6114273B2 - 抗−ｃｄ１９抗体とプリン類似体の併用治療 - Google Patents

抗−ｃｄ１９抗体とプリン類似体の併用治療 Download PDF

Info

Publication number
JP6114273B2
JP6114273B2 JP2014525432A JP2014525432A JP6114273B2 JP 6114273 B2 JP6114273 B2 JP 6114273B2 JP 2014525432 A JP2014525432 A JP 2014525432A JP 2014525432 A JP2014525432 A JP 2014525432A JP 6114273 B2 JP6114273 B2 JP 6114273B2
Authority
JP
Japan
Prior art keywords
lymphoma
medicament
fludarabine
manufacture
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014525432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525925A (ja
JP2014525925A5 (https=
Inventor
アメルスドルファー，ユタ
シュタイドル，シュテファン
ウィンデルリッヒ，マーク
クローン，スザンヌ
ロイックジャー，リサ
Original Assignee
モルフォシス・アー・ゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルフォシス・アー・ゲー filed Critical モルフォシス・アー・ゲー
Publication of JP2014525925A publication Critical patent/JP2014525925A/ja
Publication of JP2014525925A5 publication Critical patent/JP2014525925A5/ja
Application granted granted Critical
Publication of JP6114273B2 publication Critical patent/JP6114273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2014525432A 2011-08-16 2012-08-14 抗−ｃｄ１９抗体とプリン類似体の併用治療 Active JP6114273B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16
US61/523,862 2011-08-16
EP11177660.5 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (3)

Publication Number Publication Date
JP2014525925A JP2014525925A (ja) 2014-10-02
JP2014525925A5 JP2014525925A5 (https=) 2015-10-01
JP6114273B2 true JP6114273B2 (ja) 2017-04-12

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525432A Active JP6114273B2 (ja) 2011-08-16 2012-08-14 抗−ｃｄ１９抗体とプリン類似体の併用治療

Country Status (25)

Country Link
US (3) US20140227277A1 (https=)
EP (2) EP4083071A3 (https=)
JP (1) JP6114273B2 (https=)
KR (3) KR102117202B1 (https=)
CN (1) CN103703027B (https=)
AU (1) AU2012296905B2 (https=)
BR (1) BR112013033916B1 (https=)
CA (1) CA2841738C (https=)
CY (1) CY1125148T1 (https=)
DK (1) DK2744826T3 (https=)
ES (1) ES2909720T3 (https=)
HR (1) HRP20220224T1 (https=)
HU (1) HUE058855T2 (https=)
IL (1) IL230295B (https=)
LT (1) LT2744826T (https=)
MX (1) MX353589B (https=)
PL (1) PL2744826T3 (https=)
PT (1) PT2744826T (https=)
RS (1) RS63121B1 (https=)
RU (1) RU2664462C9 (https=)
SG (1) SG10201606788VA (https=)
SI (1) SI2744826T1 (https=)
SM (1) SMT202200160T1 (https=)
WO (1) WO2013024095A1 (https=)
ZA (1) ZA201401835B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
FI3916392T3 (fi) * 2016-05-30 2024-06-03 Incyte Corp Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
US12358983B2 (en) * 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
LT3630177T (lt) * 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
EA202090020A1 (ru) 2017-07-10 2020-04-28 Интернэшнл - Драг - Дивелопмент - Байотек Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
CA3255552A1 (en) * 2021-12-22 2023-06-29 Incyte Corporation TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
CA2769595A1 (en) * 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
US20110135739A1 (en) * 2009-11-06 2011-06-09 Bennett Carter Oral Formulations of a Hedgehog Pathway Inhibitor

Also Published As

Publication number Publication date
KR20140071368A (ko) 2014-06-11
RU2014103490A (ru) 2015-09-27
US20240424012A1 (en) 2024-12-26
LT2744826T (lt) 2022-04-25
CN103703027A (zh) 2014-04-02
HUE058855T2 (hu) 2022-09-28
RU2664462C9 (ru) 2018-09-28
CN103703027B (zh) 2018-01-12
ES2909720T3 (es) 2022-05-10
PT2744826T (pt) 2022-05-19
US20200352975A1 (en) 2020-11-12
US20140227277A1 (en) 2014-08-14
JP2014525925A (ja) 2014-10-02
KR20200060779A (ko) 2020-06-01
SMT202200160T1 (it) 2022-05-12
AU2012296905B2 (en) 2017-01-05
ZA201401835B (en) 2015-06-24
WO2013024095A1 (en) 2013-02-21
NZ617771A (en) 2016-01-29
RU2664462C2 (ru) 2018-08-17
DK2744826T3 (da) 2022-03-28
RS63121B1 (sr) 2022-05-31
IL230295B (en) 2018-03-29
EP4083071A3 (en) 2023-02-22
BR112013033916B1 (pt) 2022-11-16
KR102117202B1 (ko) 2020-06-01
CA2841738C (en) 2022-12-06
SI2744826T1 (sl) 2022-05-31
CY1125148T1 (el) 2024-12-13
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
PL2744826T3 (pl) 2022-05-30
MX353589B (es) 2018-01-19
HRP20220224T1 (hr) 2022-04-29
BR112013033916A2 (pt) 2017-11-28
EP2744826B1 (en) 2022-02-09
KR20190094478A (ko) 2019-08-13
CA2841738A1 (en) 2013-02-21
EP2744826A1 (en) 2014-06-25
EP4083071A2 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
JP6114273B2 (ja) 抗−ｃｄ１９抗体とプリン類似体の併用治療
US20240366756A1 (en) Combinations and uses thereof
JP2014525925A5 (https=)
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
US11224654B2 (en) Combinations and uses thereof
JP2014525926A5 (https=)
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK1195322A (en) Combination therapy with an anti-cd19 antibody and a purine analog
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog
HK1195322B (en) Combination therapy with an anti-cd19 antibody and a purine analog

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170316

R150 Certificate of patent or registration of utility model

Ref document number: 6114273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250